0
Signin
countryflagUS

18889881171

AAPL 165.84 0.5091% MSFT 400.96 0.461% GOOG 157.95 1.4321% GOOGL 156.28 1.4212% AMZN 177.23 1.4889% NVDA 795.18 4.3543% META 481.73 0.1372% TSLA 142.05 -3.4002% TSM 129.75 1.6053% LLY 731.33 0.6912% V 272.33 0.9452% AVGO 1224.46 1.6394% JPM 189.41 1.9429% UNH 491.23 -1.9755% NVO 125.26 2.0781% WMT 60.14 1.0247% LVMUY 168.89 0.4222% XOM 120.57 0.5756% LVMHF 851.89 0.4528% MA 456.75 0.2986%

Terns Pharmaceuticals Inc

Healthcare US TERN

4.82USD
0.26(5.70%)

Last update at 2024-04-22T20:01:00Z

Day Range

4.484.85
LowHigh

52 Week Range

3.2614.04
LowHigh

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -59.98700M -49.65000M -39.75800M -68.83900M -18.08500M
Minority interest - 0.00000M 0.52M 14.12M 14.32M
Net income -60.34500M -50.15800M -40.57100M -68.81900M -17.71100M
Selling general administrative 22.41M 19.55M 9.00M 8.66M 3.90M
Selling and marketing expenses - - - - -
Gross profit - 1.00M - - -
Reconciled depreciation 1.03M 0.51M 0.39M 0.20M 0.07M
Ebit -63.06100M -50.37200M -37.02500M -70.19700M -18.45500M
Ebitda -62.02900M -49.86000M -36.63100M -70.00200M -18.39000M
Depreciation and amortization 1.03M 0.51M 0.39M 0.20M 0.07M
Non operating income net other 2.04M - - - -
Operating income -62.02900M -49.86000M -37.02500M -70.19700M -18.45500M
Other operating expenses 62.03M 50.86M 37.02M 70.20M 18.45M
Interest expense -2.04200M 0.72M 2.21M 1.57M 0.00000M
Tax provision 0.36M 0.51M 0.81M -0.02000M -0.06700M
Interest income 2.11M 0.17M 0.06M 1.20M 0.33M
Net interest income 2.11M 0.17M 0.06M 1.20M 0.33M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.36M 0.51M 0.81M -0.02000M -0.06700M
Total revenue 0.00000M 1.00M 0.00000M 0.00000M 0.00000M
Total operating expenses 62.03M 50.86M 37.02M 70.20M 18.45M
Cost of revenue - - - - -
Total other income expense net 2.04M 0.21M -2.73300M 1.36M 0.04M
Discontinued operations - - - - -
Net income from continuing ops -60.34500M -50.15800M -40.57100M -68.81900M -18.01800M
Net income applicable to common shares -60.34500M -50.15800M -29.35200M -68.61100M -17.71100M
Preferred stock and other adjustments - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 287.03M 168.07M 92.29M 23.90M 89.07M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 2.07M 0.95M 0.33M 0.46M 0.16M
Total liab 10.08M 7.77M 23.70M 19.70M 16.84M
Total stockholder equity 276.94M 160.30M 68.59M 4.21M 72.23M
Deferred long term liab - - - - -
Other current liab 6.16M 4.69M 8.17M 3.31M 1.46M
Common stock 0.00500M 0.00300M - - -
Capital stock 0.00500M 0.00300M 186.03M 94.97M 94.97M
Retained earnings -242.41800M -182.07300M -131.91500M -91.86200M -23.25100M
Other liab 1.07M 0.95M 0.88M 0.63M 0.14M
Good will - - - - -
Other assets 0.04M 0.09M 0.25M 0.72M 0.34M
Cash 143.24M 47.70M 74.85M 12.33M 82.52M
Cash and equivalents - - - - -
Total current liabilities 8.47M 6.82M 22.82M 4.95M 2.38M
Current deferred revenue - - 0.84M - -
Net debt -142.03000M -47.69900M -61.97400M -12.32700M -82.52200M
Short term debt 0.66M - 12.88M - -
Short long term debt - - 12.88M - -
Short long term debt total 1.21M - 12.88M - -
Other stockholder equity 520.18M 174.64M 14.60M 1.21M 0.46M
Property plant equipment 0.76M 1.05M 1.18M 0.96M 0.26M
Total current assets 285.19M 166.93M 90.87M 22.22M 88.48M
Long term investments - - - - -
Net tangible assets 276.94M 172.16M -117.44100M -90.76000M -22.73700M
Short term investments 139.88M 118.28M 0.00000M 7.32M 4.36M
Net receivables - - 12.72M - -
Long term debt - - - - -
Inventory - - 2.97M - -
Accounts payable 1.65M 2.13M 0.94M 1.64M 0.91M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -0.82200M -0.33800M -0.12400M -0.10600M 0.06M
Additional paid in capital - - - - -
Common stock total equity 0.00500M - - - -
Preferred stock total equity - - - - -
Retained earnings total equity -242.41800M - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.04M 0.09M 0.25M 0.72M 0.34M
Deferred long term asset charges - - - - -
Non current assets total 1.84M 1.14M 1.42M 1.68M 0.60M
Capital lease obligations 1.21M - - - -
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -21.99700M -119.35600M 7.28M -2.95600M -4.53200M
Change to liabilities 0.69M 1.73M -0.45300M 0.63M 0.49M
Total cashflows from investing activities -22.27200M -119.69600M 6.69M -3.85600M -4.77600M
Net borrowings 0.24M -12.88000M 16.88M 0.06M 0.06M
Total cash from financing activities 167.09M 134.39M 85.52M 0.06M 99.76M
Change to operating activities -0.31500M -3.15200M 6.21M 1.15M -0.98600M
Net income -60.34500M -50.15800M -40.57100M -68.81900M -18.01800M
Change in cash 95.54M -27.15500M 62.48M -70.14700M 77.02M
Begin period cash flow 47.70M 74.85M 12.38M 82.52M 5.50M
End period cash flow 143.24M 47.70M 74.85M 12.38M 82.52M
Total cash from operating activities -49.10900M -41.82700M -29.80900M -66.22200M -18.07100M
Issuance of capital stock 167.25M 136.36M 69.38M 0.00000M 87.65M
Depreciation 1.03M 0.51M 0.39M 0.20M 0.07M
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables - - - - -
Sale purchase of stock 0.24M - - - -
Other cashflows from financing activities -0.40100M 10.91M 16.14M 0.06M 99.76M
Change to netincome 10.77M 9.24M -5.91100M 0.33M -0.07300M
Capital expenditures 0.28M 0.34M 0.58M 0.90M 0.24M
Change receivables - - - - -
Cash flows other operating -0.71000M - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes 95.71M - - - -
Change in working capital -1.03700M -1.42500M 5.06M 1.77M -0.35200M
Stock based compensation 10.77M 8.15M 1.69M 0.67M 0.23M
Other non cash items 0.08M 0.88M 2.92M -0.04000M -0.30700M
Free cash flow -49.38400M -42.16700M -30.39300M -67.12200M -18.31500M

Fundamentals

  • Previous Close 4.56
  • Market Cap407.23M
  • Volume534901
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-95.01500M
  • Revenue TTM1.00M
  • Revenue Per Share TTM0.04
  • Gross Profit TTM 1.00M
  • Diluted EPS TTM-1.15

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
TERN
Terns Pharmaceuticals Inc		 0.26 5.70% 4.82 - - 302.64 1.51 337.47 -1.3075
NVO
Novo Nordisk A/S		 2.55 2.08% 125.26 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 3.76 3.07% 126.26 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 5.64 1.43% 399.92 30.40 24.75 10.68 6.25 9.52 20.36
CSLLY
CSL Ltd		 2.35 2.71% 89.17 42.45 26.95 7.05 5.80 7.85 26.51

Reports Covered

Stock Research & News

View All

Profile

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of oncology, non-alcoholic steatohepatitis (NASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in clinical development for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.

Terns Pharmaceuticals Inc

1065 East Hillsdale Boulevard, Foster City, CA, United States, 94404

Key Executives

Name Title Year Born
Mr. Senthil Vel Sundaram CEO & Director 1978
Dr. Erin Quirk M.D. Pres & Head of R&D 1971
Mr. Seokho Yoon Esq. COO, Gen. Counsel & Sec. 1978
Dr. Weidong Zhong Ph.D. Co-Founder & Exec. Officer 1966
Dr. Mark Joseph Vignola CFO & Treasurer 1978
Dr. Jeffrey R. Jasper Ph.D. Sr. VP & Head of Research NA
Ms. Diana Chung Sr. VP & Chief Devel. Officer NA
Dr. Kerry Russell M.D., Ph.D. Chief Medical Officer NA

Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).